Lay trial navigators funded per centre, evaluated in a randomised trial
A trained non-clinical guide who explains trials, arranges logistics and keeps in touch could make the difference between a patient hearing about a trial and actually joining one.
Fund one lay navigator per 300 new cancer patients at community and safety-net hospitals, with a defined role: identify potentially eligible patients from matching tools, explain trials in plain language, coordinate screening logistics and follow up. Patient navigation improves timeliness of cancer care; the specific effect on trial enrolment has small positive studies and deserves a definitive randomised test.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Trials do not represent the people who get cancer · Older, Black, Hispanic, Asian, rural, poor and multimorbid patients are under-represented, so results may not apply to them.
Pages like this
not linked directly; found by shared links- IdeaStop excluding people with a prior cancer, controlled HIV, or treated hepatitis
Shares American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaCommunity health workers and trusted local organisations paid to recruit for trials
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaAt least a third of pivotal-trial sites in community and rural settings
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaRemove blanket exclusions for mental illness and dementia; support consent instead
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaMobile research units bring trial visits to rural towns
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaDefault-inclusive eligibility: sponsors must justify every exclusion criterion
Shares American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaA public equity index for trial sites and sponsors, tied to funding
Shares American Society of Clinical Oncology (ASCO), Trials do not represent the people who get cancer, National Cancer Institute (NIH).